In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Ajai Chari argues that it is necessary for patients to achieve a complete remission (CR) and minimum residual disease (MRD), and that transpant facilitates this.
A continuing education program is offered as a supplement to this webcast at the following location:
http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP
© 2015 Imedex, LLC.
Advertisement